Summary

Eligibility
for people ages 21-55 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Ziva Cooper, PhD (ucla)
Headshot of Ziva Cooper
Ziva Cooper

Description

Summary

The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.

Official Title

Analgesic and Subjective Effects of Terpenes Administered Alone and in Combination With THC

Details

The overall aim of this placebo-controlled study is to examine dose-dependent analgesia, intoxication, abuse liability, and pharmacokinetics of ecologically relevant doses of vaporized myrcene and beta-caryophyllene administered alone or with vaporized THC.

Keywords

Pain, Abuse, Drug, Cannabis, Analgesia, THC, Terpenes, Substance-Related Disorders, Caryophyllene, Low THC, High THC, Low Myrcene, High Myrcene, Low Beta-Caryophyllene, High Beta-Caryophyllene, Low strength THC, Higher strength THC, Low strength myrcene, High strength myrcene, Low strength BCP, High strength BCP, Low THC + Low myrcene, Low THC + High myrcene, High THC + Low myrcerne, High THC + High myrcene, Low THC + Low BCP, Low THC + High BCP, High THC + Low BCP, High THC + High BCP

Eligibility

You can join if…

Open to people ages 21-55

  • Male or non-pregnant female aged 21-55 years
  • Report non-medical use of cannabis 1-7 days per week over the 1 month prior to screening
  • Not currently seeking treatment for cannabis use
  • Urine test positive for recent cannabis use
  • Have a Body Mass Index from 18.5 - 34kg/m2.
  • Able to perform all study procedures
  • Must be using a contraceptive method (hormonal or barrier methods)

You CAN'T join if...

  • Meeting DSM-V criteria for any substance use disorder other than nicotine, caffeine, or mild CUD
  • Report using other illicit drugs in the prior 4 weeks
  • • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
  • Current licit use of cannabis primarily for medical purposes, prescription analgesics, or any medications that may affect study outcomes
  • Current pain
  • Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
  • History of an allergic reaction or adverse reaction to cannabis is exclusionary.
  • History of respiratory illness or current respiratory illness
  • History of seizure disorder or current seizure disorder
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • Currently enrolled in another research protocol
  • Current major Axis 1 disorders (mood, anxiety, or psychotic disorder)
  • Not using a contraceptive method (hormonal or barrier methods)
  • The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.

Location

  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Ziva Cooper, PhD (ucla)
    Dr. Ziva Cooper, Ph.D. is the Director of the UCLA Center for Cannabis and Cannabinoids in the Jane and Terry Semel Institute for Neuroscience and Human Behavior and Associate Professor in the UCLA Departments of Psychiatry and Biobehavioral Sciences and Anesthesiology.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT04451863
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 45 study participants
Last Updated